-- Mesoblast (ASX:MSB) said gross sales for Ryoncil, its mesenchymal stromal cell product, during the March quarter were $35.3 million, according to a Thursday Australian bourse filing.
Net revenue was $30.3 million, bringing the revenue generated during the first year of the product's launch to nearly $100 million, per the filing.
Receipts from customers were $34.6 million in the March quarter, compared with $1.5 million in the year-ago period.
Mesoblast's shares fell nearly 5% in recent trading on Thursday.